Skip to main content
Log in

Simulation of the Pharmacokinetic Profile of Methazolamide in Blood: Effect of Erythrocyte Carbonic Anhydrase Binding on Drug Disposition

  • Published:
Pharmaceutical Research Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

REFERENCES

  1. M. S. Highley and E. A. DeBruijin. Erythrocytes and the transport of drugs and endogenous compounds. Pharm. Res. 13:186–195 (1996).

    Google Scholar 

  2. P. H. Hinderling. Red blood cells: a neglected compartment in pharmacokinetics and Pharmacodynamics. Pharmacol. Ref. 49: 279–295 (1997).

    Google Scholar 

  3. P. J. Wistrand. The use of carbonic anhydrase inhibitors in ophthalmology and medicine. Ann. NY Acad. Sci. 429:609–619 (1984).

    Google Scholar 

  4. C. T. Supuran, F. Brigant, and A. Scozzafava. Sulfonamidosulfonamides as inhibitors of carbonic anhydrase isozymes I, II, and IV. J. Enzyme Inhib. 12:175–190 (1997).

    Google Scholar 

  5. S. Lindskog and P. Nyman. Metal binding properties of human erythrocyte carbonic anhydrase. Biochim. Biophys. Acta 86:462–474 (1964).

    Google Scholar 

  6. S. Lindskog, L. E. Henderson, and K. K. Kannan. Carbonic Anhydrase: The Enzymes, 3ed edition, Academic Press, New York, 1971.

    Google Scholar 

  7. P. J. Wistrand and P. Baathe. Inhibition of carbonic anhydrase activity of whole erythrocytes. Acta Pharmacol. Toxicol. 26:145–168 (1968).

    Google Scholar 

  8. W. F. Bayne, F. T. Tao, G. Rogers, L. C. Chu, and F. Fheeuwes. Time course and disposition of methazolamide in human plasma and red blood cells. J. Pharm. Sci. 70:75–81 (1981).

    Google Scholar 

  9. T. H. Maren, J. R. Haywood, S. K. Chapman, and T. J. Zimmerman. The pharmacology of methazolamide in relation to the treatment of glaucoma. Invest. Ophthalmol. Vis. Sci. 16:730–742 (1977).

    Google Scholar 

  10. S. Pradhan, S. Praohan, A. T. Wu, L. L. Lesko, M.-L. Chen, and R. L. Williams. Bioavailability measurements of methazolamide in plasma, red blood cells and whole blood: Implications for bioequivalence studies. Int. J. Pharm. 138:207–213 (1996).

    Google Scholar 

  11. D. R. Taft, S. Nordt, G. R. Iyer, and M. H. Schwenk. Blood disposition and urinary excretion kinetics of methazolamide following oral administration to human subjects. Biopharm. Drug Dispos. 19:373–380 (1998).

    Google Scholar 

  12. G. R. Iyer, R. A. Bellantone, and D. R. Taft. In vitro characterization of the erythrocyte distribution of methazolamide: a model of erythrocyte transport and binding kinetics. J. Pharmacokinet. Biopharm. 27:45–66 (1999).

    Google Scholar 

  13. L. B. Holder and S. L. Hayes. Diffusion of sulfonamides in aqueous buffers and into red cells. Mol. Pharmacol. 1:266–279 (1965).

    Google Scholar 

  14. S. Shirato, F. Kagaya, Y. Suzuki, and S. Joukou. Stevens-Johnson syndrome induced by methazolamide treatment. Arch. Ophthalmol. 4:550–553 (1997).

    Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to David R. Taft.

Rights and permissions

Reprints and permissions

About this article

Cite this article

AbuTarif, M.A., Taft, D.R. Simulation of the Pharmacokinetic Profile of Methazolamide in Blood: Effect of Erythrocyte Carbonic Anhydrase Binding on Drug Disposition. Pharm Res 19, 551–555 (2002). https://doi.org/10.1023/A:1015120418178

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1023/A:1015120418178

Navigation